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Entamoeba histolytica trophozoites are covered by lipophosphoglycan-peptidoglycan molecules which may be
key virulence factors. We found that pretreatment of severe combined immunodeficient mice bearing human
intestinal xenografts with a monoclonal antibody to the amebic lipophosphoglycan-peptidoglycan molecules
can prevent or significantly reduce the human intestinal inflammation and tissue damage that are normally
seen with E. histolytica colonic infection.
The protozoan parasite Entamoeba histolytica invades the
mucosal tissue of the human colon, causing colonic inflamma-
tion and tissue damage. E. histolytica trophozoites are covered
by complex lipophosphoglycans-proteophosphoglycans (LPGs-
PPGs), glycosylphosphatidylinositol-anchored molecules which
appear to contain a peptide moiety (2, 4, 6, 9). The amebic
LPGs-PPGs have been linked to amebic virulence, as they are
a rare example of molecules that differ significantly in structure
between the pathogenic E. histolytica and the morphologically
identical, but genetically distinct, nonpathogenic commensal
Entamoeba dispar (1, 5, 6). In addition, passive immunization
with a monoclonal antibody (EH5) to the amebic LPGs-PPGs
inhibited amebic liver abscess formation in severe combined
immunodeficient (SCID) mice (4). A critical unanswered ques-
tion is whether antibodies to the amebic LPGs-PPGs, or to any
other amebic antigen, can prevent or reduce disease in the
human colon. Here, we show that a combination of passive
immunization and direct intraluminal injection of the mono-
clonal antibody EH5 provides protection against amebic colitis
in SCID mice with human colonic xenografts (SCID-HU-INT
mice).
SCID-HU-INT mice were generated by engrafting human
colonic sections into the rear flanks and suprascapular regions
of 6- to 8-week-old SCID mice as previously described (7).
After a 12-week engraftment period, groups of eight SCID-
HU-INT mice received intraperitoneal (i.p.) and intraluminal
(human colonic xenograft) injections of 200 g of purified
monoclonal antibody EH5 or of the isotype-matched control
monoclonal antibody 1B10 (antiphosphorylcholine). A third
group of eight SCID-HU-INT mice received similar inocula-
tions with phosphate-buffered saline (PBS). Eight SCID-HU-
INT mice were not challenged with amebas and served as
uninfected controls. Twenty-four hours after antibody injec-
tions, the human colonic xenografts were challenged with 106
E. histolytica HM-1:IMSS trophozoites. After 24 h of infection,
all mice received an intraluminal (human colonic xenograft)
injection of 50 l of fluorescein isothiocyanate-labeled dextran
(FITC-dextran), and 4 h later, the animals were sacrificed and
sera were obtained for fluorescence measurement as previ-
ously described (8). The human colonic xenografts were sec-
tioned, and segments were homogenized for interleukin 8 (IL-
8), IL-1, and myeloperoxidase (MPO) assays, as previously
described (8). Colonic segments were also fixed for histology
and stained with hematoxylin and eosin as previously described
(7).
Infection of human colonic xenografts with E. histolytica
trophozoites results in marked tissue damage and inflamma-
tion, with invasion of amebas into mucosal and submucosal
layers (7, 8, 10). Elevations in levels of the proinflammatory
cytokine IL-1 and the chemokine IL-8, as well as marked
neutrophil influx into the infected human colonic xenograft,
are consistent components of infection (8). These findings
were reproduced in SCID-HU-INT mice receiving either PBS
or the control monoclonal antibody 1B10. As shown in Fig. 1A,
levels of IL-1 were significantly higher in E. histolytica-in-
fected human colonic xenografts obtained from SCID-HU-
INT mice receiving 1B10 (P  0.05) or no antibody (P  0.05)
than in those obtained from uninfected controls. In contrast,
levels of IL-1 were significantly lower in E. histolytica-infected
human colonic xenografts from SCID-HU-INT mice passively
immunized with EH5 than in animals treated with 1B10 (P 
0.05) or PBS (P  0.05) (Fig. 1A) and were not significantly
different from those seen in uninfected colonic xenografts (P
0.4). IL-8 levels (Fig. 1B) were also significantly lower in E.
histolytica-infected human colonic xenografts obtained from
SCID-HU-INT mice passively immunized with EH5 than in
those obtained from SCID-HU-INT mice treated with 1B10 (P
 0.05) or PBS (P  0.05). However, levels of IL-8 in E.
histolytica-infected human colonic xenografts from SCID-HU-
INT mice passively immunized with EH5 were higher than
those seen in uninfected human intestinal xenografts (P 
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0.05). MPO levels, a measure of neutrophil influx into the
intestinal xenografts, were significantly lower in human colonic
xenografts from SCID-HU-INT mice pretreated with EH5
than in E. histolytica-infected human colonic xenografts from
SCID-HU-INT mice pretreated with PBS (P  0.05) or the
control monoclonal antibody 1B10 (Fig. 1C). Levels of MPO in
human colonic xenografts from EH5-pretreated SCID-HU-
INT mice were not significantly different from those seen in
uninfected human colonic xenografts (P 0.3). Tissue damage
caused by E. histolytica infection of human colonic xenografts
results in a loss of the intestinal permeability barrier and can be
quantified by measuring the flux of FITC-dextran from the
lumen of the xenograft to the serum of the SCID-HU-INT
mouse (8). We found significant differences in damage to E.
histolytica-infected human colonic xenografts between SCID-
HU-INT mice treated with EH5 and those receiving PBS or
1B10, with higher levels of FITC-dextran seen in the sera of
the PBS (P  0.01)- or 1B10 (P  0.01)-treated SCID-HU-
INT mice (Fig. 1D). Pretreatment with EH5 did not provide
complete protection against damage to the intestinal perme-
ability barrier, as levels of FITC-dextran were significantly
higher in E. histolytica-infected, EH5-treated SCID-HU-INT
mice than in uninfected SCID-HU-INT mice (P  0.05).
Examination of histological sections obtained from human
colonic xenografts from SCID-HU-INT mice treated with
1B10 consistently revealed areas of mucosal and submucosal
invasion by E. histolytica trophozoites, with mucosal damage
and inflammation (Fig. 2A). These findings did not differ from
those seen in E. histolytica-infected human colonic xenografts
from untreated SCID-HU-INT mice (data not shown) (7, 8).
Among the eight human colonic xenografts obtained from
EH5-treated SCID-HU-INT mice, sections from five showed
no evidence of invasive infection and, when ameba were seen,
they were clumped within the lumen (Fig. 2B). In three other
human colonic xenografts obtained from EH5-treated mice,
areas of amebic invasion into the mucosa and submucosa,
along with marked inflammation, were seen in some sections
and were indistinguishable from those seen in E. histolytica-
infected human colonic xenografts from 1B10- or PBS-treated
SCID-HU-INT mice (Fig. 2C).
Our data indicate that pretreatment of SCID-HU-INT mice
with a monoclonal antibody to the E. histolytica LPG-PPG
FIG. 1. Effect of passive immunization of SCID-HU-INT mice with monoclonal antibody EH5 on inflammation and tissue damage in human
colonic xenografts infected with E. histolytica. Values are the means of results for eight animals  the standard deviation for E. histolytica-infected
human colonic xenografts from SCID-HU-INT mice passively immunized with monoclonal antibody EH5, 1B10, PBS (No ab), or uninfected
human colonic xenografts. (A) Levels of IL-1, expressed as picograms of IL-1 per milligram of total protein; (B) levels of IL-8, expressed as
picograms of IL-8 per microgram of total protein; (C) levels of MPO, expressed as units of MPO per milligram of total protein; and (D) levels
of FITC in serum, expressed as nanograms of FITC per milliliter of serum per millimeter squared of tissue. All levels measured (A to D) were
significantly lower in E. histolytica-infected human colonic xenografts from SCID-HU-INT mice treated with EH5 than in E. histolytica-infected
colonic xenografts from SCID-HU-INT mice treated with the control monoclonal antibody 1B10 or with no antibody.
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molecule can significantly reduce disease in E. histolytica-in-
fected human colonic xenografts. Treatment with EH5 prior to
the initiation of amebic infection reduced the resultant para-
site-induced gut inflammation, as measured by IL-1, IL-8,
and MPO levels, and the E. histolytica-induced tissue damage,
as measured histologically and by the integrity of the mucosal
permeability barrier. These data provide direct evidence that
preexisting antibodies to a key amebic surface antigen can
protect against amebic colitis in the human intestine in vivo.
Our findings are consistent with those of recent clinical studies
in which the presence of mucosal immunoglobulin A antibod-
ies to the surface lectin of E. histolytica was associated with
resistance to reinfection with E. histolytica in Bangladeshi chil-
dren (3).
In our study, antibodies were administered i.p., as well as
directly into the lumen of the human colonic xenograft, in
order to maximize gut antibody levels. It is possible that i.p.
administration alone, or direct intraluminal administration
of EH5 alone, would have been protective, and work is in
progress to address this possibility. Antibodies to EH5 did
not completely protect all passively immunized SCID-HU-
INT mice in this study, and this was apparent from both the
analyses of IL-8 and FITC levels and the histological anal-
ysis. Where disease was detected, pathologic findings were
identical to those seen in E. histolytica-infected human co-
lonic xenografts from control SCID-HU-INT mice. There
was a correlation between histological findings of tissue
damage and higher FITC levels in the three EH5-treated
mice with invasive disease (mean, 2.6 ng of FITC/ml of
serum/mm2 of tissue [7]) and those in the five EH5-treated
SCID-HU-INT mice without signs of disease (mean, 1.32
ng/ml/mm2  0.6; P  0.05), but differences in cytokine or
MPO levels between these groups did not reach statistical
significance (data not shown). The differences in efficacy
among EH5-treated SCID-HU-INT mice were not second-
ary to differences in antibody levels, as murine immunoglob-
ulin G levels (representing EH5 in these SCID mice) in the
human intestinal xenografts were similar in all EH5-treated
mice (data not shown).
The mechanisms by which EH5 provided protection in
this setting are not clearly established, but previous studies
have shown that antibodies to the amebic LPGs-PPGs can
block amebic adherence to target cells (9). Consistent with
the idea that effector functions of antibodies may not be
necessary for protection in this setting, we have found that
Fab fragments of EH5 appear to be as effective as the intact
antibody in preventing disease (Z. Zhang and S.L. Stanley,
Jr., unpublished data). Because these studies used SCID-
HU-INT mice to investigate human colonic disease in vivo,
it remains to be established whether active immunization
with the amebic LPGs-PPGs can engender protective im-
munity against amebic colitis.
We thank Lynne Foster for technical assistance.
FIG. 2. Morphologic findings in E. histolytica-infected human co-
lonic xenografts from SCID-HU-INT mice. Photomicrographs of he-
matoxylin-and-eosin-stained sections of E. histolytica-infected human
colonic xenografts from SCID-HU-INT mice treated with 1B10 (A) or
EH5 (B and C) are shown. (A) Extensive mucosal destruction and
inflammation and multiple E. histolytica trophozoites (white arrows)
that have invaded the mucosa and submucosal tissues are visible in a
section from a 1B10-treated SCID-HU-INT mouse. (B) In an E. his-
tolytica-infected human colonic xenograft from an EH5-treated SCID-
HU-INT mouse, amebic trophozoites are clumped together in the
lumen but the mucosa remains intact and no signs of invasion are
visible. (C) In a section from a different EH-5-treated SCID-HU-INT
mouse, mucosal destruction and inflammation are present and amebic
trophozoites can be seen invading the mucosa and submucosal regions.
Magnification, 176 (all panels).
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